Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,422 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urinary Complications Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial

NCT05308979
View directory record Official record
Conditions
Overactive Bladder, Urinary Urge Incontinence, Overactive Bladder Syndrome, Urinary Incontinence, Urge, Urge Incontinence, Urinary Urgency, Urinary Frequency
Interventions
OnabotulinumtoxinA 100 UNT [Botox]
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 4 Interventional Results available

Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women

NCT01958073
View directory record Official record
Conditions
Recurrent Urinary Tract Infection
Interventions
Conjugated Estrogen Vaginal Cream, Estradiol Ring, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
La Jolla, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Oct 22, 2026, 5:03 PM EDT
Completed No phase listed Observational

Colpocleisis for Advanced Pelvic Organ Prolapse

NCT00271037
View directory record Official record
Conditions
Pelvic Organ Prolapse, Stress Urinary Incontinence
Interventions
Colpocleisis prolapse repair surgery, sling or other to treat or prevent stress incontinence
Procedure
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
21 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
6
States / cities
Birmingham, Alabama • Maywood, Illinois • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 3 Interventional Results available

Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG

NCT02449239
View directory record Official record
Conditions
Bladder Cancer
Interventions
Vicinium
Biological
Lead sponsor
Sesen Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 1 Interventional

Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma

NCT00413075
View directory record Official record
Conditions
Solid Tumor, Lymphoma
Interventions
oral belinostat
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
4
States / cities
New Haven, Connecticut • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 3 Interventional Results available

Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

NCT00910845
View directory record Official record
Conditions
Overactive Bladder
Interventions
onabotulinumtoxinA, normal saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 22, 2026, 5:03 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Efficacy of Contrast Enhanced Voiding Urosonography for Urodynamic Studies

NCT04738539
View directory record Official record
Conditions
Myelomeningocele, Neurogenic Bladder, Tethered Cord Syndrome, Bladder, Neurogenic, Urologic Diseases, Neurologic Dysfunction
Interventions
Contrast Enhanced Voiding Urosonography with Urodynamic Testing, Urodynamic Testing
Drug · Diagnostic Test
Lead sponsor
University of Virginia
Other
Eligibility
Up to 18 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

NCT05512377
View directory record Official record
Conditions
Pancreatic Neoplasms, Solid Tumors, Biliary Tract Cancer, Lung Neoplasms, Bladder Cancer
Interventions
Brigimadlin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
18
States / cities
Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer

NCT01373294
View directory record Official record
Conditions
Bladder Cancer
Interventions
Bacille Calmette-Guerrin (BCG), Lenalidomide
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Not applicable Interventional

Night Time Use of Thiazide Diuretics for Improved Reduction in Stone Risk in Stone Formers With Elevated Urine Calcium

NCT02711670
View directory record Official record
Conditions
Kidney Stones
Interventions
chlorthalidone, Hydrochlorothiazide
Drug
Lead sponsor
VA New York Harbor Healthcare System
Federal
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 2 Interventional

Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer

NCT00006105
View directory record Official record
Conditions
Bladder Cancer, Drug/Agent Toxicity by Tissue/Organ
Interventions
amifostine trihydrate, cisplatin, gemcitabine hydrochloride, adjuvant therapy
Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Platelet-Rich Plasma for Stress Urinary Incontinence

NCT05390970
View directory record Official record
Conditions
Urinary Incontinence,Stress, Urinary Incontinence
Interventions
Platelet-rich plasma injection
Procedure
Lead sponsor
Annah J. Vollstedt
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 22, 2026, 5:03 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

WI-INTUIT: Bridging Community Based Continence Promotion and Primary Care

NCT05664451
View directory record Official record
Conditions
Urinary Incontinence
Interventions
UI-Assist, Partnership Building
Behavioral · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
3
States / cities
San Diego, California • Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 22, 2026, 5:03 PM EDT
Completed No phase listed Observational

Resiliency in Patients Undergoing Radical Cystectomy for Bladder Cancer

NCT06337305
View directory record Official record
Conditions
Bladder Cancer
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

Sunitinib in Treating Patients With Locally Advanced Bladder Cancer

NCT00526656
View directory record Official record
Conditions
Bladder Cancer
Interventions
sunitinib malate
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 22, 2026, 5:03 PM EDT
Not listed Not applicable Interventional

Assessment of Urinary Polymerase Chain Reaction (PCR) and Next Generation Sequencing (NGS) Technology in the Evaluation and Management of Females With Chronic Bladder Pain and Cystitis-like Symptoms

NCT05276466
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Polymerase Chain Reaction and Next-Generation DNA Sequencing
Diagnostic Test
Lead sponsor
MicroGenDX
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Los Angeles, California • San Diego, California • Camden, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Not applicable Interventional

Effect of Repetitive Transcranial Direct Current Stimulation (tDCS) on Chronic Pelvic Pain

NCT00554320
View directory record Official record
Conditions
Chronic Pelvic Pain, Interstitial Cystitis, Post Traumatic Stress Disorder, Fibromyalgia, Irritable Bowel Syndrome
Interventions
tDCS
Procedure
Lead sponsor
Summa Health System
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2009 · Synced Oct 22, 2026, 5:03 PM EDT
Recruiting Phase 2 Interventional

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

NCT05951179
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
TARA-002
Biological
Lead sponsor
Protara Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
44
States / cities
Homewood, Alabama • Phoenix, Arizona • Queen Creek, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 22, 2026, 5:03 PM EDT
Terminated Not applicable Interventional Results available

Use of Preemptive Pudendal Nerve Block Prior to Hydrodistention for the Treatment of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)

NCT02517996
View directory record Official record
Conditions
Interstitial Cystitis, Painful Bladder Syndrome
Interventions
Lidocaine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 4 Interventional

Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects

NCT00413790
View directory record Official record
Conditions
Healthy
Interventions
Darifenacin, Tolterodine, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
162 participants
Timeline
2006 – 2007
U.S. locations
12
States / cities
Scottsdale, Arizona • Tempe, Arizona • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Not applicable Interventional

Pelvic Floor Muscle Training in Treating Urinary Incontinence in Gynecologic Cancer Survivors

NCT01806350
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor, Uterine Sarcoma, Vulvar Cancer
Interventions
questionnaire administration, standard follow-up care, educational intervention
Other · Procedure
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
30 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Lessening Incontinence by Learning Yoga

NCT01672190
View directory record Official record
Conditions
Urinary Incontinence, Stress Urinary Incontinence, Urge Urinary Incontinence, Over Active Bladder
Interventions
Yoga Therapy Program
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Early Phase 1 Interventional

Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations

NCT02646319
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Cervical Squamous Cell Carcinoma, Endometrial Carcinoma, Malignant Uterine Neoplasm, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Malignant Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Solid Neoplasm, Stage III Bladder Cancer, Stage III Prostate Cancer, Stage III Renal Cell Cancer, Stage IIIA Breast Cancer, Stage IIIA Cervical Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Breast Cancer, Stage IIIB Cervical Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Breast Cancer, Stage IIIC Ovarian Cancer, Stage IV Breast Cancer, Stage IV Ovarian Cancer, Stage IV Prostate Cancer, Stage IV Renal Cell Cancer, Stage IVA Bladder Cancer, Stage IVA Cervical Cancer, Stage IVB Bladder Cancer, Stage IVB Cervical Cancer
Interventions
Laboratory Biomarker Analysis, Nanoparticle Albumin-Bound Rapamycin, Quality-of-Life Assessment
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Lidocaine for Pessary Check Pain Reduction

NCT05493735
View directory record Official record
Conditions
Pelvic Organ Prolapse, Stress Urinary Incontinence
Interventions
Lidocaine Hcl 2% Jelly, Placebo Jelly
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 22, 2026, 5:03 PM EDT